Typical AAV Drug Product Specifications
AAV Product Analytical Strategy
This table outlines the typical quality attributes and the analytical methods used to measure them for an AAV gene therapy product. It distinguishes between primary methods used for routine QC release and orthogonal methods used for in-depth characterization, comparability, and validation support. While methods like Mass Photometry (MP), Nanoparticle Tracking Analysis (NTA), and Alkaline Agarose Gel Electrophoresis (AAGE) are crucial for characterization, they are not typically used for GMP batch release. Next-Generation Sequencing (NGS) is the established standard for comprehensive genome characterization expected in modern IND/BLA submissions.
| Quality Attribute | Purpose / Rationale | Primary Method(s) | Orthogonal Method(s) | Acceptance Criteria |
|---|---|---|---|---|
| Appearance | Confirms basic product characteristics and absence of visible contaminants. | Visual Inspection (Manual) Automated Visual Inspection (AVI) | Turbidimetry / Nephelometry (for clarity/opalescence) | Clear to slightly opalescent, essentially free of visible particulates |
| pH (potential of hydrogen) | Maintain product stability and is within a physiologically tolerated range. | Potentiometric pH measurement | – | Meets product/formulation-specific spec (commonly near neutral, e.g., ~7–8, but defined by formulation). |
| Osmolality | Ensures patient comfort and safety (isotonicity) upon injection. | Osmometry | – | Meets product/formulation-specific spec (typically near isotonic; sponsor-justified) (240 to 400 mOsm/kg) |
| Capsid Serotype Identity | Confirms the correct viral vector is being used, which dictates tissue tropism and immunogenicity. | Peptide Mapping by Liquid Chromatography-Mass Spectrometry (LC-MS) | ELISA | ELISA: Confirms binding to serotype-specific antibody. LC-MS: Confirms sequence of serotype-defining variable regions in capsid proteins. |
| Vector Genome Identity | Confirm intended transgene cassette. | Sanger Sequencing | Next-Generation Sequencing (NGS) Restriction Enzyme Mapping | Sequence matches reference; variant frequencies within predefined thresholds. Restriction map matches expected pattern. |
| Capsid Protein Ratio (VP1/VP2/VP3) | Ensures proper capsid assembly and is critical for infectivity. | Capillary Electrophoresis-Sodium Dodecyl Sulfate (CE-SDS) | Capsid Proteins Characterization by Mass Spectrometry | Within predefined ranges vs. reference standard. |
| Vector Genome Titer (Concentration/Strength) | Quantifies the active drug substance to ensure accurate patient dosing. | Digital PCR (dPCR/ddPCR) | qPCR | Reportable Value Vg/mL (within approved range) |
| Capsid Titer | Measures the total amount of Capsids to enable calculation of the full/empty ratio. | ELISA | Nanoparticle Tracking Analysis (NTA) Analytical Ultracentrifugation (AUC) | Reportable value (cp/mL) meets approved range/spec. |
| Potency | MoA-relevant biological function. | Cell-Based Potency Assays | – | Relative potency meets validated range vs. reference (commonly 80–125% during validation; sponsor-justified for release). |
| Capsid Empty/Full Ratio | A key purity and potency attribute, as only full capsids are therapeutically active. | Anion-Exchange High-Performance Liquid Chromatography (AEX-HPLC) Analytical Ultracentrifugation (AUC) | Mass Photometry (MP) Charge Detection Mass Spectrometry (CDMS) Cryo-Transmission Electron Microscopy (cryo-TEM) | The specification is product-specific and justified by clinical and manufacturing data. It is typically set as a minimum percentage of full capsids (e.g., NLT 25%) or a maximum percentage of empty capsids (e.g., NMT 75%). |
| Capsid Aggregation | To ensure safety by minimizing immunogenicity risk and to maintain potency. | Size-Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS) | Analytical Ultracentrifugation (AUC) Dynamic Light Scattering (DLS) AF4-MALS | SEC/AUC: Meets specification for % Aggregates (e.g., ≤ 5%). DLS: Z-average is within target range, low PDI, and no large aggregate peaks detected. |
| Capsid Charge Heterogeneity | Monitors PTMs and ensures a consistent charge profile, which impacts tropism and stability. | Capillary Isoelectric Focusing (cIEF) | Anion-Exchange High-Performance Liquid Chromatography (AEX-HPLC) Peptide Mapping by Liquid Chromatography-Mass Spectrometry (LC-MS) | Charge profile comparable to reference within preset criteria (main/variant peaks, apparent pI). |
| Vector Genome Integrity | Ensures the packaged DNA is full-length and able to express a functional therapeutic protein. | Next-Generation Sequencing (NGS) | Alkaline Agarose Gel Electrophoresis (AAGE) | Meets specification for % Full-Length Intact Genomes. Truncated/rearranged genomes below predefined sponsor-justified limits. |
| Capsid Post-Translational Modifications (PTMs) | To monitor and control chemical modifications on the capsid surface that can impact the product's identity, stability, potency, and safety (immunogenicity). | Peptide Mapping by Liquid Chromatography-Mass Spectrometry (LC-MS) | Capillary Isoelectric Focusing (cIEF) Anion-Exchange High-Performance Liquid Chromatography (AEX-HPLC) | A specification might be set for a specific, critical deamidation event, such as "≤ 5% Deamidation at Asn-123. |
| Capsid Thermal Stability | To confirm the capsid is properly folded and physically stable, ensuring it can protect the genome. It is a key indicator of manufacturing consistency. | Differential Scanning Fluorimetry (DSF) | Differential Scanning Calorimetry (DSC) | Tm (and/or unfolding profile) comparable to reference within preset criteria. |
| Residual Host Cell Proteins (HCPs) | To ensure safety by minimizing the risk of an immune response | Host Cell Protein (HCP) ELISA | Host Cell Proteins Characterization by Mass Spectrometry | Meets product-specific limit justified by safety/risk. Example: Not More Than (NMT) 10 ng/mg. |
| Residual Host Cell DNA (hcDNA) | To ensure safety by minimizing the risk of oncogenicity or an immune response | qPCR for Residual DNA Analysis Digital PCR (dPCR/ddPCR) | – | Meets guideline-aligned, product-specific limits (amount per dose and, where applicable, DNA size control). ≤ 10 ng/dose (per WHO guidelines); Fragment size meets WHO guideline of <200 bp. |
| Residual Plasmid DNA | To ensure safety by minimizing risks from plasmid backbone sequences | qPCR for Residual DNA Analysis | Digital PCR (dPCR/ddPCR) | Meets product-specific limit (e.g., ≤ 10 ng/dose), justified by process capability and safety assessment. |
| Residual Benzonase | To ensure safety by removing a process enzyme that could be immunogenic. | Benzonase ELISA | Mass Spectrometry for Process-Related Impurity Characterization | ≤ 0.1 ng/dose (or ≤ 0.1 U/dose) |
| Replication Competent AAV (rcAAV) | A critical safety test to ensure no replication-capable virus is administered to the patient. | Replication Competent AAV (rcAAV) Assay | – | Negative / No rcAAV Detected |
| Endotoxin | A critical safety test to prevent fever and septic shock in patients | Bacterial Endotoxin Tests (BET) | – | Does not exceed calculated limit per USP (K/M; route/dose-based). |
| Bioburden: Pre-Sterilization Microbial Control (IPC) | Ensures microbial load is acceptably low as a critical IPC prior to final sterile filtration, providing sterility assurance for the drug product. | Procedure: USP <61> Microbial Enumeration Tests | Rapid Microbiological Methods (RMMs) | Meets process-defined IPC limit (e.g., ≤ 10 CFU/100 mL), justified by process capability and with action/alert levels established by risk assessment. |
| Sterility | A critical safety test to ensure the final product is free of microbial contamination. | Sterility Tests | – | No Growth |
| Sub-Visible Particles (SVP) | To ensure safety by controlling particles that can increase the risk of immunogenicity. | Light Obscuration (LO) | Flow Imaging Microscopy (FIM) | Meets USP limits for small-volume injections (e.g., NMT 6000 ≥10 µm; NMT 600 ≥25 µm per container). |
| Extractable Volume | To ensure the patient can receive the full, labeled dose from the container. Also note AAV vials are small volumes (0.5–2 mL) | Extractable Volume Test | – | (per USP ). Not less than labeled volume. |